AJANTPHARM.NSE · Ajanta Pharma Limited

-

Please sign in to comment on AJANTPHARM.NSE

1 Comment

Admin

4 years, 1 month ago

Ajanta Pharma Limited is currently in a long term uptrend where the price is trading 23.0% above its 200 day moving average.

From a valuation standpoint, the stock is 12.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 5.4.

Ajanta Pharma Limited's total revenue rose by 15.0% to $7B since the same quarter in the previous year.

Its net income has increased by 64.2% to $2B since the same quarter in the previous year.

Finally, its free cash flow grew by 32.4% to $3B since the same quarter in the previous year.

Based on the above factors, Ajanta Pharma Limited gets an overall score of 4/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NSE
CurrencyCode	INR
ISIN	INE031B01049

PE Ratio	35.46
Target Price	3020.1667
Dividend Yield	2.1%
Beta	0.22
Market Cap	325B

ABOUT

Ajanta Pharma Limited

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

AJANTPHARM.NSE · Ajanta Pharma Limited

-

Ajanta Pharma Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ajanta Pharma Limited using a moving average strategy